Session: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality)
Aims: This study aimed to analyze the efficacy and safety of ZR chemo-free therapy with or without ASCT in newly diagnosed MCL patients.
Methods: Patients with newly diagnosed MCL were enrolled in this prospective, open-label phase II study (NCT05504603). Patients received oral zanubrutinib(160 mg twice daily) and rituximab (375 mg/m2 weekly for cycle 1 and then on day 1 of cycles 2-5, 4 weeks per cycle) as induction therapy. Then, patients who achieved complete remission (CR) or partial remission (PR) were followed by zanubrutinib maintenance for elderly (age >70y) or unfit patients until intolerable toxicities or relapsed, while ASCT was given to younger (age ≤70y) and fit patients. The primary endpoints were overall response rate (ORR) and complete response rate (CRR) at the end of cycle 3, cycle 5 and ASCT. The secondary endpoints were 2-year overall survival (OS), 2-year progression free survival (PFS) and safety profiles.
Results: Twenty-six patients with a median age of 62 years were enrolled. The majority of patients had intermediate-risk international prognostic index and stage III/IV disease. Next-generation sequencing was performed in 21 patients to detect genetic mutations including ATM (n=9, 42.9%) and TP53 (n=3, 14.3%) mutations. 21 patients completed at least 3 cycles of ZR with 19 patients achieved CR, 1 got PR and 1 got stable disease who was then taken off this trial. The ORR and CRR for a 3-cycle response were 95.5% and 90.9%, respectively. 17 patients completed the planned 5-cycle treatment with 5 patients proceeding to ASCT. Among the 17 patients, all patients achieved CR with 10 patients (58.8%) achieved minimal residue disease negative. Within a median follow-up of 18.7 months, the 2-year OS and PFS were both 100%, and the median OS and PFS were undefined. During the whole treatment, 5 cases experienced transient alanine transaminase elevation, oral mucositis and hematological toxicities, 4 cases showed pyrexia, 2 cases occurred infusion-related response, and 1 case occurred COVID-19-related pneumonia. All toxicities were transient and reversible. No atrial fibrillation and bleeding were observed.
Conclusions: This study demonstrates a favorable efficacy and tolerable safety of chemo-free regimen ZR in newly diagnosed MCL patients and expands therapeutic options for newly diagnosed MCL.
Keywords: Mantle cell lymphoma; Zanubrutinib; Rituximab; Autologous stem cell transplantation; Therapy.
Disclosures: No relevant conflicts of interest to declare.